Stryker (SYK) Q1 FY25 earnings call

Stryker delivered a strong Q1 FY25, marked by robust organic sales growth and significant margin expansion, leading to a raised full-year sales outlook. The company successfully integrated the Inari Medical acquisition and divested its U.S. Spinal Implants business, while actively managing the estimated $200 million tariff impact through various mitigation strategies. Momentum from Mako installations and new product launches is expected to drive continued performance, despite some supply chain challenges in the Medical segment.